Introduction
Past endeavours to deal with the obstacle of expensive Cluster of Difference 4 (CD4
+
) count diagnostics in resource-limited settings have left a long trail of suggested continuous CD4
+
count clinical covariates that turned out to be a potentially important integral part of the human immunodeficiency virus (HIV) treatment process during disease progression. However, an evaluation to determine the strongest candidates among these CD4
+
count covariates has not been well documented.
Methods
The Centre for the AIDS Programme of Research in South Africa (CAPRISA) initially enrolled HIV-negative (phase 1) patients into different study cohorts. The patients who seroconverted (237) during follow-up care were enrolled again into a post-HIV infection cohort where they were further followed up with weekly to fortnightly visits up to 3 months (phase 2: acute infection), monthly visits from 3–12 months (phase 3: early infection) and quarterly visits thereafter (phase 4: established infection) until antiretroviral therapy (ART) initiation (phase 5). The CD4
+
count and 46 covariates were repeatedly measured at each phase of the HIV disease progression. A multilevel partial least squares approach was applied as a variable reduction technique to determine the strongest CD4
+
count covariates.
Results
Only 18 of the 46 investigated clinical attributes were the strongest CD4
+
count covariates and the top 8 were positively and independently associated with the CD4
+
count. Besides the confirmatory
lymphocytes
, these were
basophils
,
albumin
,
haematocrit
,
alkaline phosphatase (ALP)
,
mean corpuscular volume (MCV)
,
platelets
,
potassium
and
monocytes
. Overall, electrolytes, proteins and red blood cells were the dominant categories for the strongest covariates.
Conclusion
Only a few of the many previously suggested continuous CD4
+
count clinical covariates showed the potential to become an important integral part of the treatment process. Prolonging the pre-treatment period of the HIV disease progression by effectively incorporating and managing the covariates for long-term influence on the CD4
+
cell response has the potential to delay challenges associated with ART side effects.
Electronic supplementary material
The online version of this article (10.1007/s40121-019-0235-4) contains supplementary material, which is available to authorized users.